Purple Biotech
PPBT
19 hedge funds and large institutions have $1.9M invested in Purple Biotech in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 2 closing their positions.
588% more capital invested
Capital invested by funds: $276K → $1.9M (+$1.62M)
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
19% more funds holding
Funds holding: 16 → 19 (+3)
8.73% more ownership
Funds ownership: 1.15% → 9.88% (+8.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$2.08M |
| 2 |
Morgan Stanley
New York
|
+$62.2K |
| 3 |
KWA
Kingswood Wealth Advisors
San Diego,
California
|
+$49.4K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$15.1K |
| 5 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
+$2.21K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Simplex Trading
Chicago,
Illinois
|
-$4.43K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.44K |
| 3 |
JP Morgan Chase
New York
|
-$1.6K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$221 |
| 5 |
Wells Fargo
San Francisco,
California
|
-$60 |
PPBT Hedge Fund Activity: Q4 2023 in Review
19 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Purple Biotech (PPBT) for Q4 2023, worth a combined $1.9M — up 588% from $276K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new PPBT positions and 2 closed out — a net gain of 3 holders — while 5 added to existing stakes and 2 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $2.08M. The largest seller was Simplex Trading, cutting an estimated $4.43K.
- 19 institutional investors held Purple Biotech (PPBT) as of Q4 2023, up from 16 in Q3 2023.
- Funds reported $1.9M of Purple Biotech stock for Q4 2023, up 588% quarter-over-quarter.
- 5 funds opened new Purple Biotech positions in Q4 2023 and 2 closed out, a net change of +3 holders.
- The largest Purple Biotech buyer in Q4 2023 was Armistice Capital, an estimated $2.08M added.
- The largest Purple Biotech seller in Q4 2023 was Simplex Trading, an estimated $4.43K sold.
Based on aggregated 13F filings for Q4 2023.